Glucocorticoids and Immune Checkpoint Inhibitors: A Reassuring Coexistence in Rheumatoid Arthritis
A new study provides critical data on the interaction between glucocorticoid use and the efficacy of immune checkpoint inhibitor (ICI) cancer therapy in patients with rheumatoid arthritis (RA). Researchers analyzed a cohort of 663 older Medicare patients with RA and metastatic non-small cell lung cancer (mNSCLC) who were treated with nivolumab, pembrolizumab, or atezolizumab. The analysis specifically examined whether early glucocorticoid use (within 91 days of starting ICI) was associated with worse survival outcomes. The findings revealed that, at the dosages typically used to manage RA in this population, glucocorticoids did not have a detrimental effect on survival. In adjusted models, glucocorticoid use and dosage were not associated with an increased hazard of death, offering reassurance for clinicians managing complex patients with both autoimmune disease and cancer.
Why it might matter to you: This research directly addresses a key clinical dilemma in immuno-oncology: whether suppressing inflammation and adaptive immunity with steroids undermines cancer immunotherapy. For an immunologist, it provides real-world evidence on the nuanced interplay between humoral and cell-mediated immunity, cytokine modulation, and therapeutic outcomes. The findings can inform more confident treatment strategies for patients requiring concurrent management of autoimmunity and malignancy, a scenario where understanding immune tolerance and evasion is paramount.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
